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Introduction 
 
The discovery of antibiotics is one of the greatest discoveries of modern medicine. However, since 
their discovery, it is acknowledged that bacteria have the ability to become resistant to antibiotics if 
they are not used rationally (Md Rezal et al., 2015; Godman et al 2017). Excessive and non-rational 
use of antibiotics have resulted in increasing rates of antimicrobial resistance (AMR) worldwide, with 
ongoing initiatives to address this including addressing issues of governance (WHO, 2011; Collignon 
et al.  2015; WHO, 2015;  Shallcross etal.,  2015; Jinks et al, 2016). This is essential given the low 
number of new antibiotics in development; although there are activities to try and improve the 
situation (O'Neill, 2015; Tacconelli et al., 2017). Irrational use of antibiotics includes the prescribing 
and dispensing of antibiotics for upper respiratory tract infections (URTIs), which are the principal 
infections seen in ambulatory care and are predominantly viral in origin ( Llor & Bjerrum, 2014; Dyar 
et al, 2016; Aabenhus et al., 2017). Inappropriate prescribing, as well as dispensing without a 
prescription, are enhanced by patient pressure, sub-optimal knowledge about antibiotics and viral 
infections among key stakeholder groups and fears among physicians and pharmacists that if they do 
not prescribe or dispense an antibiotic patients will go elsewhere (Jorgi et al, 2014; Yu et al, 2014; 
Hassali et al., 2015; Bai et al., 2016; Chang et al., 2017; Eslami et al., 2016; Kibuule et al. 2016).       
 
7KHFRVWVRI$05LQ(XURSHZHUHHVWLPDWHGDW¼ELOOLRQLQEXWQRZrising to ¼ELOOLRQSHU
year or higher ( Oxford & Kozlov , 2013; Gandra et al., 2014). The lack of new antibiotics alongside 
increasing AMR rates has resulted in increasing morbidity, mortality and costs to healthcare system 
(Aminov, 2010; Gandra et al., 2014; O'Neill, 2015). As a result, AMR is now seen as one of the 
biggest public health challenges (ECDC, 2016), with deaths due to resistant strains envisaged to 
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reach up to 444 million by 2050 if AMR is not addressed (Taylor et al., 2014; Fitchett & Atun, 2016). 
This is preventable with the spread of resistant strains directly correlated with increasing and irrational 
use of antibiotics (Costelloe et al., 2010; Bell et al., 2014; Llor & Bjerrum, 2014). Consequently, 
raising awareness and knowledge about AMR and rational antibiotic use among all key stakeholder 
groups should result in a reduction in AMR rates (Huttner et al., 2010; Md Rezal et al., 2015; Godman 
et al., 2017; WHO, 2018). We are already seeing multiple activities across Europe including former 
Soviet Union Republics to tackle concerns with current antibiotic use and this will continue (Huttner et 
al., 2010; Furst et al, 2015; Abilova et al., 2018; ECDC, 2018).  
 
The Republic of Srpska is one of the two constituent entities of Bosnia and Herzegovina, with an 
estimated population of approximately 1.4 million. The Republic has implemented a range of laws and 
other activities over the years to regulate health care activities, which includes enhancing the 
appropriate use of medicines through initiatives including introducing good clinical practice guidelines 
(MoHSW 1999, 2008, 2009, 2010; PABH 2008; Petrusic & Jakovljevic, 2015). Activities have also 
been ongoing in other Balkan countries; however, there are concerns with the practice of evidence 
based medicine, the cost consciousness of physicians even after cost containment policies as well as 
the principles of resource allocation among physicians, although this is changing (Jakovljevic et al, 
2016a; Jakovljevic et al., 2016b). There are also concerns with the level of co-payments among 
patients in the Balkan countries especially with high cost medicines; although this has not prevented 
pharmaceutical markets growing among the Balkan countries as seen in Bulgaria, Croatia, the 
Republic of Srpska and Serbia in recent years, including medicines for cardiovascular and respiratory 
diseases, cancer and depression (Putrik et al., 2014; Jakovljevic et al., 2015; Petrusic & Jakovljevic, 
2015; Jakovljevic and Souliotis, 2016; Kostic et al., 2017; Pejcic & Jakovljevic, 2017).  
 
Policies and programmes to improve the health of patients with limited resources in the Republic of 
Srpska include improving the availability and affordability of medicines, improving antibiotic 
prescribing and dispensing, and raising awareness on excessive antibiotic utilization and resistance. 
A summary of these initiatives are contained in Boxes 1 and 2.  The various activities have increased 
prescribing efficiency as well as enhanced prescribing in accordance with standard treatment 
guidelines, positively impacting on for instance the rate of polypharmacy in practice (Markovic-
Pekovic et al., 2012; Markovic-Pekovic et al., 2016).  
 
Box 1.  Legal framework for regulation of health care and rational medicine use in the Republic 
of Srpska 
 
x Laws, rulebooks, programs and policies for regulating the health care and rational use of 
medicines, including antibiotics, adopted by Ministry of Health and Social Welfare (MoHSW) of 
the Republic of Srpska (MoHSW, 1999, 2008; PABH, 2008; MoHSW 2009; 2010) 
x Antibiotics can only be dispensed on prescription by pharmacist. There are considerable fines if 
this is abused MoHSW 2008; PABH, 2008) 
x The Republic of Srpska Inspectorate is the responsible institution for supervising the 
implementation of this legislation 
x The MoHSW established the National Committee for AMR Control as a national expert body 
(2015) responsible for monitoring and controlling of AMR and proposing measures to improve 
rational antibiotic prescribing and utilization 
x On the proposal of the National Committee, the MoHSW adopted the national Program to 
reduce AMR resistance in the Republic of Srpska from 2016 to 2020, harmonized with the 
WHO Global Strategy for Containment of Antimicrobial Resistance (WHO, 2001) and the 
Council of Europe Recommendation's on prudent use of antimicrobial agents in human 
medicine (EC, 2002). The aim of this program is to establish and implement high-quality and 
effective health care for the population ensuring good control of AMR with an emphasis on 
rational antibiotic use. The stated objectives are to be reached through improving the 
intersectoral control on AMR and antibiotic use in healthcare as well as among veterinary 
institutions, seeking to reduce morbidity and mortality caused by multiresistant strains of 
bacteria, improving education among health workers and associates in the field of AMR, raising 
awareness on AMR and rational antibiotic use and, also, through participation of 
representatives from the Republic of Srpska in international networks and research in the field 
of AMR 
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Box 2.  Activities to improve rational antibiotic use in the Republic of Srpska 
 
Activities to enhance rational prescribing 
x The set of Clinical Guidelines (CG) with diagnostic and therapeutic principles have been 
developed for Primary Health Care physicians. These include guidelines for upper and lower 
acute respiratory infections in children (acute otitis media, tonsillopharyngitis, community 
acquired pneumonia), urinary tract infections in children, as well as urinary tract infections in 
adults (2004) 
x The list of antibiotics funded by the Health Insurance Fund of the Republic of Srpska (HIF) are 
in accordance with the CG recommendations 
x HIF adopted a positive list of medicines with reference prices comprised of List A and List B. 
List A is a basic list of medicines for which HIF covers 90% or 100% of the reference price of 
the medicine depending on the category of the insured person. List B is a supplementary list, 
which includes more expensive medicines, for which HIF covers 50% of the costs for all 
insured patients. For medicines not included in the positive list, the patient must pay 100% of 
the price. In addition, if the price of drug is higher than the reference price adopted by HIF, the 
patient has to pay the price difference. 
x The antibiotics included in List A are: doxycycline, amoxicillin, phenoxymethylpenicillin, 
benzathine-phenoxymethylpenicillin, cefalexin, sulfamethoxazole with trimethoprim and 
erythromycin. Norfloxacin is included in List B 
Activities to enhance rational dispensing 
x There is permanent education of pharmacists and pharmacy technicians on the appropriate 
management of infectious diseases to address concerns with knowledge of infectious diseases, 
especially viral infectious diseases, which has been a concern in other countries (Eslami et al., 
2016; Saleem et al., 2016; Belkina et al., 2017; Hoxha et al., 2018) 
x TKH3KDUPDFHXWLFDO$VVRFLDWLRQRIWKH5HSXEOLFRI6USVNDODXQFKHGWKHµThe Guideline for 
FRXQVHOOLQJSDWLHQWVLQWKHSKDUPDF\¶as a tool to assist pharmacy personnel to make decisions 
whether they can successfully treat patients with non-pharmacological measures and/or with 
OTC medicines, or whether to refer them to a family practitioner, in vew of concerns with self-
medication with antibiotics in the Republic (Markovic-3HNRYLF	*UXELVD'DPMDQRYLüHW
al., 2013; Markovic-Pekovic et al., 2017) 
Activities of professional associations and key stakeholder groups 
x Regular professional meetings, conferences and symposia in order to upgrade the knowledge, 
habits and attitudes of health professionals (doctors and pharmacists). 
x Publishing articles on AMR and rational antibiotic use in professional journals. 
x Discussions concerning current AMR surveillance in the Republic of Srpska among key 
stakeholder groups and agreement of specific activities to improve AMR reporting and 
monitoring.  
x The MoHSW and the Public Health Institute (PHI) marking European Antibiotic Awareness Day 
and World Antibiotic Awareness Week in November each year starting from 2013 with support 
of European Centre for Disease Prevention and Control (ECDC) 
Activities to enhance public awareness on AMR and rational antibiotic use 
x Campaigns are organized to raise awareness about AMR and rational antibiotic use among the 
general public, patient associations and health professionals.  
x Promotional materials (including flyers, infographics, fact sheets, posters, and social media), 
recommended by ECDC, are provided to patients and health professionals. 
 
Consequently, the aim of this study was to analyse total antibiotic utilization in the Republic of Srpska 
in recent years and to assess the influence of these various initiatives to improve antibiotic prescribing 
and dispensing in the Republic. Subsequently, compare the findings with those of other European and 
neighbouring countries to review potential additional measures that could be introduced in the 
Republic of Srpska if needed to further improve the rational use of antibiotics. As a result, seek to 
reduce future AMR rates. 
 
Methods 
 
This was a retrospective observational study on outpatient antibiotic utilization in the Republic of 
Srpska from 2010 to 2015, based on drug utilization data obtained from the Public Health Institute 
(PHI).  Data collection was based on quantitative and structural medicinal reports that pharmacies in 
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the Republic send to the PHI each year for collation (Petrusic & Jakovljevic, 2015). Consequently, 
includes total antibiotic utilisation in the Republic and not just prescribed antibiotics. 
 
Drug utilization analysis of the PHI data was undertaken using the ATC (Anatomical Therapeutic 
Chemical classification)/DDD (Defined Daily Dose) methodology (WHO, 2017), which is the 
internationally accepted methodology for measuring medicine utilisation within and across populations 
(Godman et al., 2014; Malo et al., 2014; Versporten et al., 2014; Abilova et al., 2018). DDDs are 
defined as the amount of drug most commonly used in adults for the most common indication. It is a 
suitable measure to describe and compare drug utilization patterns between different geographical 
areas and health facilities. Data on outpatient antibiotic utilization are expressed in DDD/1000 
inhabitants/day (DIDs) for comparative purposes (Malo et al., 2014; Versporten et al., 2014; WHO, 
2017). DU 90% (drug utilization 90%) was also used as indicator for assessing the quality of antibiotic 
prescribing, ranking antibiotics first by volume of DIDs and then by how many antibiotics were 
included in DU 90% ( Markovic-Pekovic et al., 2009; Malo et al., 2014). 
 
Antibiotic utilization and associated quality indicators were used to compare the Republic of 6USVND¶V 
utilisation patterns with that from other European countries, as well as former Soviet Union Republics, 
to place this in perspective (Adriaenssens et al.,2011a; Adriaenssens et al., 2011b; Versporten et al., 
2014; de Bie et al., 2016;; WHO Europe, 2017). The quality of antibiotic prescribing was assessed 
using the European Surveillance of Antimicrobial Consumption (ESAC), European Centre for Disease 
Prevention and Control (ECDC) and World Health Organisation (WHO) Europe quality indicators 
(Adriaenssens et al., 2011a; Adriaenssens et al., 2011b; WHO Europe, 2017; ECDC 2018). These 
included:  
x Total utilization of antibiotics expressed as DIDs, 
x Utilization of penicillins (J01C) as a % of total antibiotic use, 
x Penicillins combination utilization such as amoxicillin with clavulanic acid (co-amoxiclav) as a 
percentage of total antibiotic use, 
x Total utilization of cephalosporins expressed as DIDs, 
x Percentage utilization of third- and fourth-generation of cephalosporins vs all cephalosporins, 
x Total utilization of J01F group (macrolides, lincosamides and streptogramins) expressed as DIDs  
x Utilization of short-acting macrolides, intermediate and long-acting macrolides (erythromycin, 
clarithromycin and azithromycin) as a percentage of total antibiotic use,  
x Utilization of quinolones (J01M) expressed in DIDs as well as percentage of fluoroquinolones 
(J01MA) of total antibiotic use. 
 
A number of these indicators are due to concerns with the over use of co-amoxiclav, macrolides, third 
and fourth generation cephalosporins as well as fluoroquinolones (Adriaenssens, et al., 2011a; Malo 
et al., 2014; WHO Europe, 2017). 
 
Since multiple initiatives and reforms were instigated over time in the Republic of Srpska  with varying 
intensity, coupled with the nature of reported figures, it was impossible to undertake sophisticated 
statistical analyses such as time series analyses. As a result, more simple statistical tests, including 
trend analyses, were performed to assess the level of significance, with significance seen as p <0.05. 
This is similar to other health authority analyses where multiple interventions are conducted over time  
with no opoortunity for time series analyses ( Godman et al., 2010; Voncina et al., 2011; Bennie et al., 
2012; Godman et al., 2014; Abilova et al., 2018). 
 
No specific ethical approval was sought as only aggregated anonymised data was used for analysis, 
with Ministry of Health personnel involved in the study. This is similar to other studies of this nature 
(Godman et al., 2010; Bennie et al., 2012; Godman et al., 2014; Abilova et al., 2018).  
 
Results 
 
The total utilization of antibiotics for systemic use (J01 group) comprised 98% of total utilization of 
anti-infectives (J group). Utilization of the J01 group varied between 15.6 and 18.4 DIDs during the 
observed period (Table 1, Table 4), lower than a number of neighbouring countries (Figure 1).  
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Table 1. Total utilization of antibiotics for systemic use (J01 group) expressed in DIDs and 
percentages over the 2010 ± 2015 period 
 
ATC 
group 
2010 2011 2012 2013 2014 2015 p-values 
DIDs % DIDs % DIDs % DIDs % DIDs % DIDs % DID % 
J01C 8.18 46.5 8.34 47.6 7.97 50.6 9.97 54.2 7.86 50.3 8.16 48.7 P=0
.16 
p=0.
37 
J01D 3.01 17.2 2.45 14.0 2.10 13.4 2.63 14.3 2.06 13.2 2.27 13.5 P=0
.18 
P=0.
109 
J01M 1.46 8.3 1.64 9.4 1.46 9.3 1.51 8.2 1.61 10.3 1.71 10.2 P=0
.35 
P=0.
15 
J01F 1.70 9.7 1.78 10.2 1.49 9.5 1.70 9.3 1.55 9.9 1.61 9.6 P=0
.39 
P=0.
6 
J01A 1.69 9.6 1.55 8.9 1.39 8.9 1.31 7.1 1.27 8.1 1.60 9.5 P=0
.12 
P=0.
6 
J01E 1.20 6.8 1.41 8.0 1.05 6.7 1.05 5.7 1.03 6.6 1.03 6.2 P=0
.74 
P=0.
23 
J01X 0.24 1.4 0.25 1.4 0.23 1.5 0.18 1.0 0.21 1.3 0.30 1.8 P=0
.44 
P=0.
63 
J01G 0.09 0.5 0.10 0.5 0.03 0.2 0.05 0.3 0.04 0.3 0.08 0.5 P=0
.51 
P=0.
7 
Total 
J01 
17.6 100 17.5 100 15.7 100 18.4 100 15.6 100 16.8 100   
NB: J01A - Tetracyclines, J01C - Beta-lactam antibacterials, penicillins, J01D - Other beta-lactam 
antibacterials (cephalosporins), J01E - Sulfonamides and trimethoprim, J01F- Macrolides, 
lincosamides and streptogamins, J01G - Aminoglycoside antibacterials, J01M - Quinolone 
antibacterials, J01X - Other antibacterials. % = % of antiobiotics in that class for the year 
 
Figure 1 compares the utilisation in recent years with other neighbouring countries. 
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Figure 1 ± Antibiotic utilisation in the Republic of Srpska in 2014 and 2015 (in DIDs) versus 
neighbouring countries in similar years [Taken from Furst et al., 2015; WHO Europe, 2017; ECDC, 
2018] 
 
 
 
The penicillins (J01C) were the most consumed antibiotics comprising 50% of total antibiotic 
utilization on average, followed by other beta-lactam antibiotics (14%). The highest utilization of 
penicillins was observed in 2013 with 10.0 DIDs, while the lowest (7.9 DIDs) observed in 2014. The 
utilization of broad-spectrum penicillins (J01CA) was 6.04 DIDs on average (Table 2). Amoxicillin 
constituted 95% of this group (5.76 DIDs) (Figure 2), followed by ampicillin (0.28 DIDs). Co-amoxiclav 
(J01CR02) ranged from 1.1 to 1.9 DIDs from 2010 to 2015 (Figure 2), while beta-lactamase sensitive 
penicillins (J01CE) comprised 5% of total antibiotic use (Table 2), with phenoxymethylpenicillin the 
most prescribed antibiotic of this group. 
 
Figure 2. Amoxicillin vs. co-amoxiclav utilization expressed in DIDs over the 2010-2015 period 
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Table 2. Utilization of penicillins (J01CA) expressed in DIDs over the 2010 ± 2015 period  
 
ATC 
group 
Pharmacological 
group 
DIDs P-
values 
2010 2011 2012 2013 2014 2015 
J01CA 
Penicillins with 
extended spectrum 
5.62 6.10 5.88 7.56 5.38 5,72 
p=0.99 
J01CR 
Combinations of 
penicillins, incl. beta-
lactamase inhibitors 
1.14 1.33 1.23 1.47 1.66 1.89 
P=0.004 
J01CE 
Beta-lactamase 
sensitive penicillins 
1.42 0.91 0.85 0.94 0.82 0.56 
P=0.03 
J01CF 
Beta-lactamase 
resistant penicillins 
0.01 < 0.01 < 0.01 < 0,01 < 0,01 < 0,01 
P=0.918 
Total J01C 8.2 8.3 8.0 10.0 7.9 8.2  
 
Utilization of cephalosporins (J01D) decreased from 3.0 DIDs in 2010 to 2.3 DIDs in 2015 (Table 1, 
Table 4). The first-generation cephalosporins (J01DB) were the most used within J01D group 
(67.6%), of which cefalexin was the only one used. Its utilization decreased from 2.0 DIDs in 2010 to 
1.5 DIDs in 2015, which represents a reduction of 25%. Overall, utilization of the second and third 
generation of cephalosporins (J01DC and J01DD) also declined during this period. Regarding the 
second-generation cephalosporins, cefuroxime had very stable utilization ranging from 0.45 to 0.56 
DIDs during the study period, while utilization of cefaclor decreased from 0.15 in 2010 to 0.05 DIDs in 
2015 (67%). Overall, third generation cephalosporins constituted 7.9% of total cephalosporins, or 
1.2% on average of total antibiotics (Table 4). After declining from 2010 to 2014, utilization of the third 
generation cephalosporins subsequently increased in 2015 (Table 4). The fourth generation 
cephalosporins, monobactams and carbapenems, were not used at all. 
 
Erythromycin was the most used macrolide (0.68 DIDs) followed by azithromycin (0.57 DIDs) and 
clarithromycin (0.32DIDs). Overall, macrolides constituted 9.4% of total antibiotic utilization, which is 
about five times lower than the penicillins. The use of the macrolides was highest in 2011 (1.7 DIDs) 
and then dropped thereafter to 1.5 DIDs (Table 1).  
 
Doxycycline was the most used tetracycline (J01A), with quinolone utilisation (J01M) ranging from 1.5 
DDDs in 2010 to 1.7 DIDs in 2015 (Table 1), of which 90% were fluoroquinolones. Ciprofloxacin was 
the most prescribed fluoroquinolone. The only sulphonamide (J01E) was a combination of 
sulfamethoxazole with trimethoprim, which accounted 7% of total antibiotic utilization (Table 1). 
Utilization of aminoglycoside antibiotics (J01G) and other antibiotics (J01X) was negligible (Table 1). 
 
DU90% shows the number of antibiotics included in 90% of total utilization.  Over the observed 
period, ten antibiotics were constantly included in the DU90% profile. DU90% included ten antibiotics 
in 2013, eleven in 2014 and twelve during the rest of the study years. Amoxicillin, amoxicillin with 
clavulanic acid (co-amoxiclav), cephalexin, ciprofloxacin, doxycycline and sulfamethoxazole with 
trimethoprim were the most used antibiotics over the observed period (Table 3).  
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Table 3. Antibiotic utilization within Drug Utilization (DU90%) profile, expressed in DIDs over 
the 2010-2015 period 
 
2010 2011 2012 2013 2014 2015 
DID % DID % DID % DID % DID % DID % 
amoxi
cillin 
5.14 29.26 5.72 32.67 5.60 35.59 7.38 40.12 5.19 33.20 5.54 33.07 
amoxi
cillin, 
clavul
anic 
acid 
1.14 6.49 1.33 7.60 1.23 7.82 1.47 7.99 1.66 10.62 1.89 11.28 
cefale
xin 
2.05 11.67 1.58 9.02 1.31 8.32 1.93 10.49 1.44 9.21 1.53 9.13 
ciprof
loxaci
n 
0.96 5.46 1.13 6.45 1.04 6.61 1.11 6.03 1.20 7.68 1.23 7.34 
doxyc
ycline 
1.61 9.16 1.48 8.45 1.22 7.75 1.20 6.52 1.11 7.10 1.20 7.16 
sulfa
meth
oxazo
le, 
trimet
hopri
m 
1.20 6.83 1.41 8.05 1.05 6.67 1.05 5.71 1.03 6.59 1.03 6.15 
azithr
omyci
n 
0.30 1.71 0.64 3.65 0.50 3.18 0.56 3.04 0.63 4.03 0.76 4.54 
phen
oxym
ethyl-
penici
llin 
1.17 6.66 0.71 4.05 0.66 4.19 0.74 4.02 0.55 3.52 0.53 3.16 
cefur
oxime 
0.49 2.79 0.56 3.20 0.51 3.24 0.54 2.94 0.48 3.07 0.45 2.69 
erythr
omyci
n 
1.07 6.09 0.71 4.05 0.61 3.88 0.74 4.02 0.55 3.52 0.43 2.57 
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According to the quality indicators, the total utilization of beta-lactam antibiotics (penicillins and 
cephalosporins), macrolides and fluoroquinolones, expressed as percentage of total antibiotic use, 
was very stable over the observed period (Table 4). However, the use of co-amoxiclav increased from 
6.5% of total antibiotic utilization in 2010 to 11.3% in 2015, which is a concern in this trend continues. 
At the same time, the use of erythromycin decreased for 37.2% within the macrolide group, while 
azithromycin rose proportionally (Tables 3 and 4).  
 
Table 4. Quality indicators for antibiotic utilization in the Republic of Srpska over the 2010-
2015 period  
 
QUALITY INDICATOR 2010 2011 2012 2013 2014 2015 
Total utilization of antibiotics (J01) 
(DIDs) 
17.6 17.5 15.7 18.4 15.6 16.8 
Total utilization of beta-lactam 
antibiotics (penicillins ± J01C and 
cephalosporins ± J01D) as a % of total 
antibiotic use 
63.7 61.6 64.0 68.5 63.5 62.3 
Total utilization of penicillins (J01C) as 
a % of total antibiotic use 
46.5 47.6 50.6 54.2 50.3 48.7 
Utilization of combination penicillins 
(co-amoxiclav ± J01CR02) as % of 
total antibiotic use 
6.5 7.6 7.8 8.0 10.6 11.3 
Total utilization of cephalosporins ± 
J01D (DIDs)  
3.0 2.5 2.1 2.6 2.1 2.3 
Utilization of 3rd and 4th generation 
cephalosporins (J01DD and J01DE) 
as % of total antibiotic use 
1.9 1.1 1.3 0.6 0.6 1.4 
Utilization of 3rd and 4th generation of 
cephalosporins as % of total 
cephalosporin use 
11.0 7.7 9.5 4.1 4.6 10.4 
clarit
hrom
ycin 
- - 0.35 2.00 0.33 2.10 - - 0.30 1.92 0.35 2.10 
ampic
illin 
0.48 2.73 0.38 2.17 0.28 1.78 - - - - - - 
norflo
xacin 
0.30 1.71 - - - - - - - - - - 
ambr
oxol, 
doxyc
ycline 
- - - - - - - - - - 0.38 2.27 
DU90
% 
1-12 1-12 1-12 1-10 1-11 1-12 
90.56 91.36 91.13 90.88 90.46 91.46 
Other
s (%) 
13-32 13-31 13-31 11-30 12-30 13-30 
9.44 8.64 8.87 9.12 9.54 8.54 
Total 
(%) 
1-32 1-31 1-31 1-30 1-30 1-30 
100 100 100 100 100 100 
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Total utilization of macrolides, 
lincosamides and streptogramins- 
J01F (DIDs) 
1.7 1.8 1.5 1.7 1.6 1.6 
Total utilization of erythromycin 
(J01FA01), clarithromycin (J01FA09) 
and azithromycin (J01FA10) as % of 
total antibiotic use 
9.3 9.7 9.1 8.9 9.4 9.2 
Total utilization of erythromycin as % 
of total macrolide use, with 
corresponding increase in 
clarithromycin and azithromycin 
64.7 40.9 42.0 45.0 36.7 27.5 
Total utilization of quinolones J01M ± 
(DIDs) 
1.5 1.6 1.5 1.5 1.6 1.7 
Total utilization of fluoroquinolones 
(J01MA) as % of total antibiotic 
utilization 
7.4 8.4 8.4 7.4 9.3 9.4 
 
Figures 3 to 5 and Table 5 provide comparisons with similar and neighbouring countries to the 
Republic of Srpska in recent years. 
  
Figure 3 - % utilisation of beta-lactams as a % of total antibiotic utilisation across countries 
[taken from Furst et al., 2015; WHO Europe, 2017; ECDC, 2018] 
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Table 5 ± Utilisation of third and fourth generation cephalosporins as a % of total 
cephalosporins (J01D) [taken from Furst et al., 2015; WHO Europe, 2017; ECDC, 2018] 
 
Country and year % 
Republic of Srpska 2014 4.6% 
Republic of Srpska 2015 10.4% 
Serbia 2014 16% 
Albania 2014 30% 
Turkey 2014 38% 
Montenegro 2014 40% 
Moldova 2014 46% 
Uzbekistan 2014 63% 
Azerbaijan 2014 76% 
Belarus 2014 79% 
Kyrgyzstan 2014 81% 
Azerbaijan 2015 82% 
 
Figure 4 ± Utilisation of quinolones as a % of total antibiotic utilisation across countries [taken 
from Furst et al., 2015; WHO Europe, 2017; ECDC, 2018] 
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Figure 5 - % Combination penicillins (co-amoxiclav J01CR02) as a % of total antibioitc 
utilisation  [taken from Furst et al., 2015; WHO Europe, 2017; ECDC, 2018] 
 
 
 
Discussion 
 
Total antibiotic utilisation was relatively constant during the study period in the Republic of Srpska 
(Table 1), with minor fluctuations, and an overall a decline in total utilization of 5% between 2010 and 
2015, with a corresponding reduction in expenditure on antibiotics (J01) in 2013 versus 2009 
(Petrusic & Jakovljevic, 2015). In addition, antibiotic utilisation in the Republic was lower than a 
number of neighbouring countries and former Soviet Union Republics in recent years (Figure 1). This 
is in direct contrast with total worlwide antibiotic utilisation, which rose by 36% during the past decade 
(Laxminarayan et al., 2016). There appears to be several reasons for this in the Republic of Srpska.  
Firstly, health care in the Repubic is well regulated by a number of policies, strategies, guidelines and 
normatives (Boxes 1 and 2), despite limited available resources for such initiatives. The Law on health 
care and the Law of health insurance enables all patients to have adequate health care access in the 
Republic, including medicines and other types of treatment (MoHSW, 1999; MoHSW 2009 ). Standard 
treatment guidelines for the most common clinical problems in ambulatory care were developed by 
family physician associations and adopted by Ministry of Health and Social Welfare (MoHSW) in 2004 
in order to improve the quality and rationality of physician prescribing. Based on these guidelines, only 
recommended and essential antibiotics were included in the HIF positive list of medicines to 
emphasize rational prescribing and reduce unnecessary expenditure to help ensure cost-efficient 
antibiotics are available for all citizens in the Republic. This aproach is similar to the situation seen in 
some European countries and regions with multiple initiatives to enhance the quality and efficiency of 
prescribing ( Gustafsson et al., 2011; Bjorkhem-Bergman et al., 2013). However, we are aware that 
there is variable implementation of guidelines among a number of European countries in practice 
(Francke et al., 2008; Sermet et al., 2010; van Dijk et al, 2011; Brusamento et al., 2012; Fitzgerald et 
al., 2014; Baker et al., 2015). In addition, as mentioned, there are concerns with issues of evidence 
based medicine among physicians in the Balkan countries (Jakovljevic et al., 2016a; Jakovljevic et al., 
2016b); however, this appears not to be the case in the Republic of Srpska certainly with respect to 
antibiotic prescribing. 
 
Secondly, a number of initiatives and activities have been implemented in the Repubic in order to 
improve knowledge, attitudes and practices of pharmacists to reduce antibiotic self-medication and 
improve approrpiate management of patients with URTIs (Boxes 1 and 2), especially as pharmacists 
are often the first health professional patients see with their URTI (Markovic-Pekovic et al, 2017). This 
includes the tightening of self-medication regulations, with self-medication known to appreciably 
increase antibiotic utilisation in URTIs and similar conditions (Kalaba et al., 2011; Kibuule et al., 2016; 
Markovic-Pekovic et al., 2017). This is different to Albania where self-medication is common 
particularly for URTIs, and there are considerable concerns with pharmacy knowledge regarding 
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antibiotics and viruses ( Jorgji et al., 2014; Hoxha et al., 2015;  Hoxha et al., 2018). There are also 
concerns with continuing self-mediciation in Serbia (Kalaba et al., 2011). Education among 
pharmacists also reduced the extent of self-medication with antibiotics in Kenya especially for URTIs 
(Mukokinya et al., 2018).   
 
These combined initiatives also appeared to result in high use of beta-lactam antibiotics and limited 
use of third and fourth generation cephalosporins and fluorquinolones in the Republic in recent years 
in accordance with agreed quality indictaros (Table 4), comparable or improved prescribing versus 
neighbouring countries (Figures 3 and 4, Table 5). We have also seen reduced expenditure on first 
and second generation cephalosporins in Serbia between 2007 and 2012, although also reduced 
prescribing on combinations of penicillins (J01CR) and penicillins with extended spectrums (J01CA) 
(Jakovljevic and Souliotis, 2016).The DU90% profile (Table 3) shows that first and second generation 
antibiotics were mainly used, reflecting the antibiotics reimbursed by HIF and contained in current 
clinical guidelines (Box 2). This is similar to the situation with other medicines when prescribing is 
restricted and/ or where there are high co-payments to rationalize pharmacotherapy (Sakshaug et al., 
2007; Martikainen et al. 2010; Wettermark et al., 2010; Kalaba et al., 2012; Markovic-Pekovic et al., 
2012; Moon et al., 2014). In Slovenia, prescribing restrictions for co-amoxiclav, the cephalosporins, 
macrolides, and fluoroquinolones, also significantly reduced their use (Furst et al., 2015). These 
findings support other publised studies which suggest that multiple initiatives are typically needed to 
positively influence prescribing (Bero et al., 1998; Barton, 2001; Francke et al., 2008; Godman et al., 
2013; Godman et al., 2014; Moon et al., 2014). 
 
Amoxicillin, which is included in the HIF positive A list, was the most utilised penicillin in the Republic 
of Srpska, with utilization of co-amoxiclav approximately 4 times lower than amoxicillin. The low 
utilisation of co-amoxiclav in the Republic compares favourably with neighbouring countries (Figure 
5).  However, there are concerns with the rise in its utilization in recent years (Tables 2 and 4 and 
Figure 2). This is due to concerns with increasing side-effects and resistance leading to co-amoxiclav 
now being recommended as a second line antibiotic after amoxicillin in a number of guidelines 
(Andrade & Tulkens, 2011; Desrosiers et al., 2011; NHS Scotland, 2014; GGC Prescribing, 2017; 
ECDC, 2018). There are also concerns with currently limited prescribing of phenoxymethyl penicillin in 
the Republic (Table 3) as it is likely that a high proprtion of infections seen in ambulatory care are 
likely to be URTIs (Llor & Bjerrum, 2014; Rezal et al., 2015; Dyar et al., 2016). These will be areas to 
address if these trends (Figure 2) continue. 
 
Encouragingly, given concerns with the development and spread of resistant strains of C.difficle 
(Dancer, 2001; Batzing-Feigenbaum et al., 2016), there were low rates of cephalosporin utilisation, 
with rates remaining relatively constant over the study period (Tables 1 and 4). In addition, as 
mentioned, the Republic of Srpska had low utilization of third and fourth generation of cephalosporins 
in recent years (Table 4), comparing favourably with neighbouring countries (Table 5). There was also 
relatively low utilization of macrolides (J01F), with rates decreasing in recent years but not reaching 
statistical significance (Tables 1 and 4).  This is similar to Serbia with expenditure on macrolides 
falling in recent years (Jakovljevic and Souliotis, 2016). However, the prescribing of azithromycin is 
increasing, with a simultaneous decrease in utilization of erythromycin (Tables 3 and 4), resulting in 
the utilization of azithromycin exceeding erythromycin in 2014 and 2015. This is causing concern with 
increasing resistance rates as well as side-effects with the macrolides (Albert & Schuller, 2014; 
ECDC, 2018).  
 
Concerns with the recent increased utilisation of co-amoxiclav and azithromycin, as well as higher use 
of fluoroquinolones than some neighbouring countries (Table 1), has already resulted in planned 
activities, with their implementation and impact being monitored. These ongoing and planned 
activities (Box 2) should further help with enhancing appropriate antibiotic use in the Republic of 
Srpska. Planned activities also include programes to improve inter-sectoral control over antibiotic 
utilisation, including both health and veterinary sectors, as well as improved undergraduate and 
postgraduate education regarding antibiotics and AMR. The development of specific indicators for 
monitoring antibiotic utilization is also planned, building on existing quality indicators for NCDs, as well 
as monitoring hospital resistance patterns. These data will be used to revise and update the clinical 
guidelines for rational antibiotic use in the Republic. Planned activities also include improving the 
information technology for monitoring of AMR and antibiotic consumption. The findings will 
subsequently be shown to health professionals to emphasize what has been done so far and to 
discuss further activities. This is similar to activities in for instance in Sweden with its monitoring of 
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prescribing in the regions together with the development of quality indicators to improve physician 
prescribing practices (Godman et al., 2009; Wettermark et al., 2009; Gustafsson et al., 2011; Eriksen 
et al., 2017).  
 
Alongside this, pharmacists and family physicians will be encouraged to comunicate more to their 
patients about rational antibiotic use and AMR, building on current initiatives. This will be combined 
with planned activities to further raise public awareness regarding the potential harmful effects of 
excessive, inappropriate, and unnecessary use of antibiotics. These programmes will also be the 
subject of future research projects. 
 
We believe this study clearly shows that even lower income countries such as the Republic of Srpska 
can appreciably improve rational medicine utilization by introducing multiple interventions and 
initiatives, acting as an exemplar to other European countries and wider.  
 
We are aware of a number of limitations of this study. These include no access to prescribing data to 
be able to assess the quality of antibiotic prescribing against standard treatment guidelines. However, 
we believe our methodology, including the use of total antibiotic utilisation via the PHI datasets, as 
well as comparisons with neighbouring countries, adds robustness to our findings and conclusions.   
 
In conclusion, without looking specifically at prescribing indications, we believe there appears to be 
rational antibiotic utilization in the Republic of Srpska in recent years compared to neighbouring 
countries, with favourable use of penicillins combined with moderate or low use of co-amoxiclav, 
cephalosporins including third and fourth generation cephalosporins, macrolides and quinolones. This 
again demonstrates that multiple interventions with key stakeholder groups can favourably improve 
medicine utilisation patterns.  
 
Acknowledgements and conflicts of interest 
 
9DQGD0DUNRYLü-3HNRYLüLVemployed by the Ministry of Health and Social Welfare in the Republic of 
Srpska and /MXELFD%RMDQLü 0LUMDQDĈHUPDQRYLüDQG-DQMD%RMDQLü are employed by the Public Health 
Institute. The authors have no other conflicts of interest to declare. 
 
There was no external funding for this research. 
 
References 
  
Aabenhus, R., Hansen, M. P., Saust, L. T., & Bjerrum, L. (2017). Characterisation of antibiotic 
prescriptions for acute respiratory tract infections in Danish general practice: a retrospective registry 
based cohort study. NPJ Prim Care Respir Med, 27(1), 37.  
 
Abilova, V., Kurdi, A., & Godman, B. (2018). Ongoing initiatives in Azerbaijan to improve the use of 
antibiotics; findings and implications. Expert Rev Anti Infect Ther, 16(1), 77-84.  
 
Adriaenssens, N., Coenen, S., Tonkin-Crine, S., Verheij, T. J., Little, P., & Goossens, H. (2011a). 
European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for 
outpatient antibiotic prescribing. BMJ Qual Saf, 20(9), 764-772. d 
 
Adriaenssens, N., Coenen, S., Versporten, A., Muller, A., Vankerckhoven, V., & Goossens, H. 
(2011b). European Surveillance of Antimicrobial Consumption (ESAC): quality appraisal of antibiotic 
use in Europe. J Antimicrob Chemother, 66 Suppl 6, vi71-77.  
 
Albert, R. K., & Schuller, J. L. (2014). Macrolide antibiotics and the risk of cardiac arrhythmias. Am J 
Respir Crit Care Med, 189(10), 1173-1180. doi:10.1164/rccm.201402-0385CI 
 
Aminov, R. I. (2010). A brief history of the antibiotic era: lessons learned and challenges for the future. 
Front Microbiol, 1, 134.  
 
Andrade, R. J., & Tulkens, P. M. (2011). Hepatic safety of antibiotics used in primary care. J 
Antimicrob Chemother, 66(7), 1431-1446.  
 
15 
 
Bai, Y., Wang, S., Yin, X., Bai, J., Gong, Y., & Lu, Z. (2016). Factors associated with doctors' 
knowledge on antibiotic use in China. Sci Rep, 6, 23429.  
 
Baker, A., Chen, L. C., Elliott, R. A., & Godman, B. (2015). The impact of the 'Better Care Better 
Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-
experimental design. BMC Health Serv Res, 15, 367.  
 
Barton, S. (2001). Using clinical evidence. BMJ, 322(7285), 503-504.  
 
Batzing-Feigenbaum, J., Schulz, M., Schulz, M., Hering, R., & Kern, W. V. (2016). Outpatient 
Antibiotic Prescription. Dtsch Arztebl Int, 113(26), 454-459.  
 
Bell, B. G., Schellevis, F., Stobberingh, E., Goossens, H., & Pringle, M. (2014). A systematic review 
and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infectious 
Diseases, 14, 13-13.  
 
Belkina, T., Duvanova, N., Karbovskaja, J., Tebbens, J. D., & Vlcek, J. (2017). Antibiotic use practices 
of pharmacy staff: a cross-sectional study in Saint Petersburg, the Russian Federation. BMC 
Pharmacology & Toxicology, 18, 11. doi:10.1186/s40360-017-0116-y 
 
Bennie, M., Godman, B., Bishop, I., & Campbell, S. (2012). Multiple initiatives continue to enhance 
the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev 
Pharmacoecon Outcomes Res, 12(1), 125-130.  
 
Bero, L. A., Grilli, R., Grimshaw, J. M., Harvey, E., Oxman, A. D., & Thomson, M. A. (1998). Closing 
the gap between research and practice: an overview of systematic reviews of interventions to promote 
the implementation of research findings. The Cochrane Effective Practice and Organization of Care 
Review Group. BMJ, 317(7156), 465-468.  
 
Bjorkhem-Bergman, L., Andersen-Karlsson, E., Laing, R., Diogene, E., Melien, O., Jirlow, M., . . . 
Gustafsson, L. L. (2013). Interface management of pharmacotherapy. Joint hospital and primary care 
drug recommendations. Eur J Clin Pharmacol, 69 Suppl 1, 73-78.  
 
Brusamento, S., Legido-Quigley, H., Panteli, D., Turk, E., Knai, C., Saliba, V., et al. (2012). Assessing 
the effectiveness of strategies to implement clinical guidelines for the management of chronic 
diseases at primary care level in EU Member States: a systematic review. Health Policy, 107(2-3), 
168-183.  
 
Chang, J., Ye, D., Lv, B., Jiang, M., Zhu, S., Yan, K., et al. (2017). Sale of antibiotics without a 
prescription at community pharmacies in urban China: a multicentre cross-sectional survey. J 
Antimicrob Chemother, 72(4), 1235-1242.  
 
Collignon, P., Athukorala, P. C., Senanayake, S., & Khan, F. (2015). Antimicrobial resistance: the 
major contribution of poor governance and corruption to this growing problem. PLoS One, 10(3), 
e0116746.  
 
Costelloe, C., Metcalfe, C., Lovering, A., Mant, D., & Hay, A. D. (2010). Effect of antibiotic prescribing 
in primary care on antimicrobial resistance in individual patients: systematic review and meta-
analysis. BMJ, 340, c2096.  
 
Dancer, S. J. (2001). The problem with cephalosporins. J Antimicrob Chemother, 48(4), 463-478.  
 
ĂŵũĂŶŽǀŝđ ?a ? ? ?ĂũƌĂŬƚĂƌĞǀŝđ ?ŽǎŽǀŝđd ? ? ? ? ? ? ? ?dŚĞ'ƵŝĚĞůŝŶĞĨŽƌĐŽƵŶƐĞůůŝŶŐ patients in the 
pharmacy. Pharmaceutical Association of the Republic of Srpska, Banja Luka  
 
de Bie, S., Kaguelidou, F., Verhamme, K. M., De Ridder, M., Picelli, G., Straus, S. M., et al. (2016). 
Using Prescription Patterns in Primary Care to Derive New Quality Indicators for Childhood 
Community Antibiotic Prescribing. Pediatr Infect Dis J, 35(12), 1317-1323.  
 
16 
 
Desrosiers, M., Evans, G. A., Keith, P. K., Wright, E. D., Kaplan, A., Bouchard, J., et al. (2011). 
Canadian clinical practice guidelines for acute and chronic rhinosinusitis. J Otolaryngol Head Neck 
Surg, 40 Suppl 2, S99-193.  
 
Dyar, O. J., Beovic, B., Vlahovic-Palcevski, V., Verheij, T., & Pulcini, C. (2016). How can we improve 
antibiotic prescribing in primary care? Expert Rev Anti Infect Ther, 14(4), 403-413.  
 
EC Council Recommendation (EC) 2002/77 of 15 November 2001 on the prudent use of antimicrobial 
agents in human medicine (2002) OJ L34/13. Available at URL: http://eur-lex.europa.eu/legal-
content/EN/TXT/HTML/?uri=URISERV:c11569&from=EN  
 
ECDC. (2016). EARS-Net surveillance data. Summary of the latest data on antibiotic resistance in the 
European Union. Available at URL: http://ecdc.europa.eu/en/eaad/antibiotics-get-informed/antibiotics-
resistance-consumption/Documents/antibiotics-EARS-Net-summary-2016.pdf  
 
ECDC. (2018) Quality indicators for antibiotic consumption in the community in Europe. Available at 
URL: http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance-and-consumption/antimicrobial-
consumption/esac-net-database/Pages/quality-indicators-primary-care.aspx.    
 
Eriksen, J., Gustafsson, L. L., Ateva, K., Bastholm-Rahmner, P., Ovesjo, M. L., Jirlow, M., et al. 
(2017). High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year 
retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open, 7(4), 
e014345.  
 
Eslami, N., Eshraghi, A., Vaseghi, G., Mehdizadeh, M., Masjedi, M., & Mehrpooya, M. (2016). 
Pharmacists' Knowledge and Attitudes Towards Upper Respiratory Infections (URI) in Iran: A Cross 
Sectional Study. Rev Recent Clin Trials, 11(4), 342-345.  
 
Fitchett, J. R., & Atun, R. (2016). Antimicrobial resistance: opportunity for Europe to establish global 
leadership. Lancet Infect Dis, 16(4), 388-389.  
 
Fitzgerald, A., Lethaby. A., Cikalo, M., Glanville, J., Wood, H. (2014) Review of Systematic Reviews 
Exploring the Implementation/Uptake of Guidelines. Yorh Health Economics Consortium. Available at 
URL: https://www.nice.org.uk/guidance/ph56/evidence/evidence-review-2-431762366.    
 
Francke, A. L., Smit, M. C., de Veer, A. J. E., & Mistiaen, P. (2008). Factors influencing the 
implementation of clinical guidelines for health care professionals: A systematic meta-review. BMC 
Medical Informatics and Decision Making, 8, 38-38.  
 
Furst, J., Cizman, M., Mrak, J., Kos, D., Campbell, S., Coenen, S., et al. (2015). The influence of a 
sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: 
findings and implications. Expert Rev Anti Infect Ther, 13(2), 279-289.  
 
Gandra, S., Barter, D. M., & Laxminarayan, R. (2014). Economic burden of antibiotic resistance: how 
much do we really know? Clin Microbiol Infect, 20(10), 973-980.  
 
Godman, B., Wettermark, B., Hoffmann, M., Andersson, K., Haycox, A., & Gustafsson, L. L. (2009). 
Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global 
relevance. Expert Rev Pharmacoecon Outcomes Res, 9(1), 65-83. doi:10.1586/14737167.9.1.65 
 
Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010). Comparing 
policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes 
seen and global implications. Expert Rev Pharmacoecon Outcomes Res, 10(6), 707-722.  
 
Godman, B., Bishop, I., Finlayson, A. E., Campbell, S., Kwon, H. Y., & Bennie, M. (2013). Reforms 
and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their 
influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res, 13(4), 469-
482.  
 
17 
 
Godman, B., Wettermark, B., van Woerkom, M., Fraeyman, J., Alvarez-Madrazo, S., Berg, C., et al. 
(2014). Multiple policies to enhance prescribing efficiency for established medicines in Europe with a 
particular focus on demand-side measures: findings and future implications. Front Pharmacol, 5, 106.  
 
Godman, B., Fadare, J., Kibuule, D., Irawati. L., Mubita, M., Ogunleye, O., et al. (2017) Initiatives 
across countries to reduce antibiotic utilization and resistance patterns; impact and implications. Ps 
539-576 in Drug Resistance in Bacteria, Fungi, Malaria, and Cancer - Arora, Sajid, & Kalia Eds. 
Publisher Springer Nature. ISBN 978-3-319-48682-6. Available at URL:  
https://link.springer.com/content/pdf/bfm%3A978-3-319-48683-3%2F1.pdf 
 
Greater Glasgow and Clyde Prescribing. (2017) Co-Amoxiclav. Available at URL:  
http://www.ggcprescribing.org.uk/formulary/infections/antibacterial-drugs/  
 
Gustafsson, L. L., Wettermark, B., Godman, B., Andersen-Karlsson, E., Bergman, U., Hasselstrom, J., 
et al. (2011). The 'wise list'- a comprehensive concept to select, communicate and achieve adherence 
to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol 
Toxicol, 108(4), 224-233.  
 
Hassali, M. A., Kamil, T. K., Md Yusof, F. A., Alrasheedy, A. A., Yusoff, Z. M., Saleem, F., et al. 
(2015). General practitioners' knowledge, attitude and prescribing of antibiotics for upper respiratory 
tract infections in Selangor, Malaysia: findings and implications. Expert Rev Anti Infect Ther, 13(4), 
511-520.  
 
+R[KD,0DODM$.UDMD%%LQR62OXND00DUNRYLü-3HNRYLü9*RGPDQ%$UH
SKDUPDFLVWV¶JRRGNQRZOHGJHDQGDZDUHQHVVRQDQWLELRWLFVWDNHQIRUJUDQWHG"7KHVLWXDWLRQLQ
Albania and future implications across countries. Journal of Global Antimicrobial Resistance (In 
Press) 
 
HOXHA, I., Malaj A., TAKO, R., MALAJ, L. (2015). Survey on how antibiotics are dispensed in 
community pharmacies in Albania. International Journal of Pharmacy and Pharmaceutical Sciences, 
7(7), 449-450.  
 
Huttner, B., Goossens, H., Verheij, T., & Harbarth, S. (2010). Characteristics and outcomes of public 
campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet 
Infect Dis, 10(1), 17-31.  
 
Jakovljevic, M. B., Djordjevic, N., Jurisevic, M., & Jankovic, S. (2015). Evolution of the Serbian 
pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes 
Res, 15(3), 521-530.  
 
Jakovljevic, M.B, Vukovic M., Chen Ching, C., Antunovic, M., Simic Dragojevic, V., Radovanovic 
Velickovic, R., et al. (2016a). Do Health Reforms Impact Cost Consciousness of Health Care 
Professionals? Results from a Nation-Wide Survey in the Balkans. Balkan Med Jn, 33, 8- 
 
Jakovljevic, M., Lazarevic, M., Milovanovic, O., & Kanjevac, T. (2016b). The New and Old Europe: 
East-West Split in Pharmaceutical Spending. Front Pharmacol, 7, 18.  
 
Jakovljevic, M., Souliotis, K. (2016). Pharmaceutical expenditure changes in Serbia and Greece 
during the global economic recession SEEJPH, 1-17. Available at URL: 
file:///C:/Users/mail/Downloads/document.pdf.  
 
Jinks, T., Lee, N., Sharland, M., Rex, J., Gertler, N., Diver, M., et al. (2016). A time for action: 
antimicrobial resistance needs global response. Bull World Health Organ, 94(8), 558-558a. 
doi:10.2471/blt.16.181743 
 
Jorgji, K., Bebeci, E., Apostoli, P., & Apostoli, A. (2014). Evaluation of use of antibiotics without 
prescription among young adults in Albania case study: Tirana and Fier District. Hippokratia, 18(3), 
217-220.  
 
18 
 
Kalaba, M., Bajcetic, M., Sipetic, T., Godman, B., Coenen, S., Goossens, H. (2011). High rate of self 
purchasing of oral antibiotics in Serbia: implications for future policies. PPRI Conference. Vienna 
2011. Available at URL: 
http://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKonferenz/general_PPRI%20
conference%202011%20Abstract%20book.pdf.    
 
Kalaba, M., Godman, B., Vuksanovic, A., Bennie, M., & Malmstrom, R. E. (2012). Possible ways to 
enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? J Comp Eff 
Res, 1(6), 539-549.  
 
Kibuule, D., Kagoya, H. R., & Godman, B. (2016). Antibiotic use in acute respiratory infections in 
under-fives in Uganda: findings and implications. Expert Rev Anti Infect Ther, 14(9), 863-872 
 
Kostic, M., Djakovic, L., Sujic, R., Godman, B., & Jankovic, S. M. (2017). Inflammatory Bowel 
Diseases (Crohn s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. 
Appl Health Econ Health Policy, 15(1), 85-93. 
 
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Rottingen, J. A., Klugman, K., & Davies, S. 
(2016). Access to effective antimicrobials: a worldwide challenge. Lancet, 387(10014), 168-175. 
 
Llor, C., & Bjerrum, L. (2014). Antimicrobial resistance: risk associated with antibiotic overuse and 
initiatives to reduce the problem. Ther Adv Drug Saf, 5(6), 229-241. 
 
Malo, S., Bjerrum, L., Feja, C., Lallana, M. J., Abad, J. M., & Rabanaque-Hernandez, M. J. (2014). 
The quality of outpatient antimicrobial prescribing: a comparison between two areas of northern and 
southern Europe. Eur J Clin Pharmacol, 70(3), 347-353.  
 
Markovic-Pekovic, V., Stoisavljevic-Satara, S., & Skrbic, R. (2009). Utilisation of cardiovascular 
medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study. Pharmacoepidemiol Drug 
Saf, 18(4), 320-326 
 
Markovic-Pekovic, V., Skrbic, R., Godman, B., & Gustafsson, L. L. (2012). Ongoing initiatives in the 
Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev 
Pharmacoecon Outcomes Res, 12(5), 661-671.  
 
Markovic-Pekovic, V., & Grubisa, N. (2012). Self-medication with antibiotics in the Republic of Srpska 
community pharmacies: pharmacy staff behavior. Pharmacoepidemiol Drug Saf, 21(10), 1130-1133. 
doi:10.1002/pds.3218 
 
Markovic-Pekovic, V., Skrbic, R., Petrovic, A., Vlahovic-Palcevski, V., Mrak, J., Bennie, M., et al. 
(2016). Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the 
future. Expert Rev Pharmacoecon Outcomes Res, 16(5), 609-618. 
 
Markovic-Pekovic, V., Grubisa, N., Burger, J., Bojanic, L., & Godman, B. (2017). Initiatives to Reduce 
Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications. J Res Pharm Pract, 
6(2), 120-125. 
 
Martikainen, J. E., Saastamoinen, L. K., Korhonen, M. J., Enlund, H., & Helin-Salmivaara, A. (2010). 
Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care, 
48(9), 761-766.  
 
Md Rezal, R. S., Hassali, M. A., Alrasheedy, A. A., Saleem, F., Md Yusof, F. A., & Godman, B. (2015). 
Physicians' knowledge, perceptions and behaviour towards antibiotic prescribing: a systematic review 
of the literature. Expert Rev Anti Infect Ther, 13(5), 665-680. 
 
Ministry of Health and Social Welfare (MoHSW). (1998). Law on Health Insurance [in Serbian]. The 
Republic of Srpska Official Gazzette 1999, No 18. 
 
Ministry of Health and Social Welfare. (2008) Pharmacy Practice Law [in Serbian]. The Republic of 
Srpska  Official Gazzette 2008, No 119 
19 
 
 
Ministry of Health and Social Welfare. (2009) Law on Health Care [in Serbian]. The Republic of 
Srpska Official Gazzette, No 106.  
 
Ministry of Health and Social Welfare. (2010). Law on Protection of Population from Infectious 
Diseases [in Serbian]. The Republic of Srpska Official Gazzette 2010, No 14.  
 
Moon, J. C., Godman, B., Petzold, M., Alvarez-Madrazo, S., Bennett, K., Bishop, I., et al. E. (2014). 
Different initiatives across Europe to enhance losartan utilization post generics: impact and 
implications. Front Pharmacol, 5, 219. 
 
Mukokinya, M.M., Opanga, S., Oluka, M., Godman, B. (2018) Dispensing of antimicrobials in Kenya; a 
cross sectional pilot study and its implications. Journal of Research in Pharmacy Practice (In Press) 
 
NHS Scotland. (2014) National Therapeutic Indicators 2014/ 2015. Available at URL: 
http://www.sehd.scot.nhs.uk/publications/DC20141201nti.pdf  
 
O'Neill, J. (2015). Securing new drugs for future generations: the pipeline of antibiotics. The review of 
antimicrobial resistance. Available at URL: https://amr-
review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATI
ONS%20FINAL%20WEB_0.pdf.  
 
Oxford, J., & Kozlov, R. (2013). Antibiotic resistance--a call to arms for primary healthcare providers. 
Int J Clin Pract Suppl(180), 1-3.  
 
Parliamentary assembly of Bosnia and Herzegovina. (2008) Law on Medicines and Medical Devices 
[in Serbian, Croatian, Bosnian]. Bosnia and Herzegovina Official Gazzette 2008, No 58.  
 
Pejcic, A. V., & Jakovljevic, M. (2017). Pharmaceutical expenditure dynamics in the Balkan countries. 
J Med Econ, 20(10), 1013-1017.  
 
Petrusic, T., & Jakovljevic, M. (2015). Budget Impact of Publicly Reimbursed Prescription Medicines in 
the Republic of Srpska. Front Public Health, 3, 213.  
 
Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Pavlova, M., Uhlig, T., & Boonen, A. (2014). Inequities 
in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis, 73(1), 
198-206.  
 
Rezal, R. S., Hassali, M. A., Alrasheedy, A. A., Saleem, F., Yusof, F. A., Kamal, M., et al. (2015). 
Prescribing patterns for upper respiratory tract infections: a prescription-review of primary care 
practice in Kedah, Malaysia, and the implications. Expert Rev Anti Infect Ther, 13(12), 1547-1556.  
 
Saleem, Z., Saeed, H., Ahmad, M., Yousaf, M., Hassan, H. B., Javed, A., et al. (2016). Antibiotic Self-
Prescribing Trends, Experiences and Attitudes in Upper Respiratory Tract Infection among Pharmacy 
and Non-Pharmacy Students: A Study from Lahore. PLoS One, 11(2), e0149929.  
 
Sakshaug, S., Furu, K., Karlstad, O., Ronning, M., & Skurtveit, S. (2007). Switching statins in Norway 
after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol, 64(4), 476-481.  
 
Sermet, C., Andrieu, V., Godman, B., Van Ganse, E., Haycox, A., & Reynier, J. P. (2010). Ongoing 
pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health 
Policy, 8(1), 7-24.  
 
Shallcross, L. J., Howard, S. J., Fowler, T., & Davies, S. C. (2015). Tackling the threat of antimicrobial 
resistance: from policy to sustainable action. Philosophical Transactions of the Royal Society B: 
Biological Sciences, 370(1670), 20140082.  
 
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., et al. (2017). 
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant 
bacteria and tuberculosis. Lancet Infect Dis.  
20 
 
 
Taylor J, H. M., Yerushalmi E, Smith R, Bellasio J, Vardavas R, et al. (2014). Estimating the economic 
costs of antimicrobial resistance: model and results. Available at URL: 
http://www.rand.org/content/dam/rand/pubs/research_reports/RR900/RR911/RAND_RR911.pdf.  
 
van Dijk, L., de Jong, J. D., Westert, G. P., & de Bakker, D. H. (2011). Variation in formulary 
adherence in general practice over time (2003-2007). Fam Pract, 28(6), 624-631. 
 
Versporten, A., Bolokhovets, G., Ghazaryan, L., Abilova, V., Pyshnik, G., Spasojevic, T., et al. (2014). 
Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO 
Regional Office for Europe. Lancet Infect Dis, 14(5), 381-387. doi:10.1016/s1473-3099(14)70071-4 
 
Voncina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S., et al. (2011). Influence of 
demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for 
the future. Expert Rev Pharmacoecon Outcomes Res, 11(4), 469-479. doi:10.1586/erp.11.42 
 
Wettermark, B., Godman, B., Neovius, M., Hedberg, N., Mellgren, T. O., & Kahan, T. (2010). Initial 
effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. 
Health Policy, 94(3), 221-229. doi:10.1016/j.healthpol.2009.09.014 
 
Wettermark, B., Pehrsson, A., Juhasz-Haverinen, M., Veg, A., Edlert, M., Tornwall-Bergendahl, G., et 
al (2009). Financial incentives linked to self-assessment of prescribing patterns: a new approach for 
quality improvement of drug prescribing in primary care. Qual Prim Care, 17(3), 179-189.  
 
WHO. (2001). Global Strategy for Containment of Antimicrobial Resistance. Geneva, 2001. Available 
at URL: http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf 
 
WHO. (2011). European strategic action plan on antibiotic resistance. Available at URL: 
http://www.euro.who.int/__data/assets/pdf_file/0008/147734/wd14E_AntibioticResistance_111380.pdf 
 
WHO. (2015) Global action plan on antimicrobial resistance. Available at URL: 
http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/.    
 
WHO. (2017) WHO Collaborating Centre for Drug Statistics Methodology. ATC/ DDD Index. Available 
at URL: https://www.whocc.no/.    
 
WHO Europe. (2017) Antimicrobial Medicines Consumption (AMC) Network. Available at URL: 
http://www.euro.who.int/en/publications/abstracts/antimicrobial-medicines-consumption-amc-network.-
amc-data-20112014-2017.    
 
WHO. (2018). Antimicrobial resistance. Fact Sheet. 2018. Available at URL: 
http://www.who.int/mediacentre/factsheets/fs194/en/.  
 
Yu, M., Zhao, G., Stålsby Lundborg, C., Zhu, Y., Zhao, Q., & Xu, B. (2014). Knowledge, attitudes, and 
practices of parents in rural China on the use of antibiotics in children: a cross-sectional study. BMC 
Infectious Diseases, 14, 112-112.  
 
 
